NOV 1 9 2007

FORM PTO-14 (REV. 7-80)	ANTHAB	EMARK				TMENT D TRAD		ATTY. DOCKET NO. 200.1079CON4	SERIAL NO.: 10/056,348					
LIST OF PRIO	R ART	CITED						APPLICANT(S): Ronald M. BURCH, et al.						
(Use several s								FILING DATE: January 25, 2002	GROUP: 1639					
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOC	UMENT	NUME	3ER			DATE	NAME	CLASS	SUBCLASS FILING DATE IF APPROPRIATE			
AND DESCRIPTION OF THE PROPERTY OF THE PROPERT	AA											THE PROPERTY OF THE PROPERTY O		
	ĀB	NO. 100.000									CONTROL OF THE PROPERTY OF THE			
	AC		300000000	20000000000000000000000000000000000000	- Section 1					CONTROL OF THE PROPERTY OF THE				
PERFIGN PATENT DOCUMENTS														
		DOC	DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					NAME OF TAXABLE PARTY.	DESCRIPTION OF THE PROPERTY OF	ACCESSORY OF THE PARTY OF THE P			900000		YES	NO	
	AD	-	SOCIO DE CONTROL DE CO	SE CONTRACTOR DE LA CON										
	AE CONTRACTOR				<u></u>							***************************************		
SASSESSESSESSESSESSESSESSESSESSESSESSESS	AF			<u></u>	<u> </u>		L						200000000	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	Degner, Frank, et al., "Efficacy and Tolerability of Meloxicam in an Observational, Controlled Cohort Study in Patier Rheumatic Disease", Clin Therapeutics (Nov 2000) 22: 400-410.											nts with		
/S.L./	АН	Lane Diclo	Lanes, Stephan et al., "Baseline Risk of Gastrointestinal Disorders Among New Users of Meloxicam, Ibuprofen, Diclofenac, Naaproxen and Indomethacin", Pharmacoepidemiology and Drug Safety (2000) 9:113-117.											
	AI		Translation of Office Action dated November 1, 2001, issued in connection with Russian Federation Patent Application No. 2000109552.											
	AJ	STN:	File Re	egistry	printo	ut of Re	egistr	y Number 162	054-19-5 (June 14, 200	04).				
	AK	Abstr Mice,	ract of	SANTO mation	DS et	al., "An earch (tinoci 1998)	iceptive effect , 47(7) pages	of meloxicam, in neuro 302-307, Chem. Abst.	genic and in Vol. 129 (Co	flammatory nocic lumbus, OH)	eptive mod	els in	
	AL	Mice," Inflammation Research (1998), 47(7) pages 302-307, Chem. Abst. Vol. 129 (Columbus, OH) FRÖLICH, J.C., "A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes," TiPS, January 1997, vol. 18, pages 30-34.												
	AM	Abstract of OGINO K. et al., "Evaluation of pharmacological profile of meloxicam as an anti-inflammatroy agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1," Pharmacology 55(1):44-53, July 1997.												
	AN	Abstract of ISAKSON P. et al., "Discovery of a better aspirin," Advances in Prostaglandin, Thromboxane, & Leukotriene Research 23:49-54, 1995.												
	AO	Abstract of JOUZEAU J.Y. et al., "Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drus," Drugs 53(4):563-82, April 1997.												
	AP	Abstract of DVORNIK D.M., "Tissue selective inhibition of prostaglandin biosynthesis by etodolac," Journal of Rheumatology, Supplement 47:40-7, February 1997.												
V	AQ	Richy, F., et al., "Time dependent risk of gastrointestinal complications induced by non-steroid anti-inflammatory drug use: a consensus statement using a meta-analytic approach", Ann Rhuem Dis (2004) 64:759-766.												
EXAMINER				/Su	e Liu	1 /			DATE CONSIDERED 05/27/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

NOV 1 9 2007 W

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE										ATTY. DOCKET 200.1079CON4	NO.:	SERIAL NO.: 10/056,348			
LIST OF PRIOR ART CITED BY APPLICANT										APPLICANT(S): Ronald M. BURCH, et al.					
(Use several sheets if necessary)										FILING DATE: January 25, 2002	2	GROUP: 1639			
		-						U.S. F	PATENT DO	CUMENTS					
*EXAMINE R INITIAL	_	DOCUMENT NUMBER DATE							DATE	NAME	CLASS	SUBCLASS	UBCLASS FILING DATE IF APPROPRIATE		
The second secon	BA									***************************************	 	- TATO DE CONTROL DE C	Description of the second		
	ВВ		SON OF THE PERSON NAMED IN	NO COORDING	XX0000000					-	- CONTROL CONT	O CONTROL OF THE PROPERTY OF T			
	ВС					0000000000	NO CONTRACTOR OF THE PERSON NAMED IN	pananananananananananananananananananan	Po	THE PERSON NAMED OF THE PE	500 500 500	<u> </u>			
	FOREIGNIPATENT										T		IDOLACO TRANCLATION		
		DOCUMENT NUMBER						OKOSOO CO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA		
	 	W00000000	955555555555	SKINDERSKINE.	September 1							***************************************	YES	NO	
	BD		\dashv								_		000000000000000000000000000000000000000	SERVICE SERVIC	
O STATE OF THE PARTY OF THE PAR	BE	<u> </u>		 OT	NED I	DDIO!	D ADT	· (Inclus	ding Author	Titla Data Partina	nt Pages Et	<u> </u>	<u> </u>		
/S.L.	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) /S.L./ BF Goodman & Gillman's (1996), The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill, New York, pp. 654-655.														
/S.L./	101	Abstract of FLOWER R. J., "New directions in cyclooxygenase research and their implications for NSAID-ç													
	BG	Italiar	Italian Journal of Gastroenterology, 28 Suppl. 4:23-7, December 1996.												
	вн	Abstract of KURUMBAIL R.G. et al., "Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents," Nature, 384(6610):644-8, December 19-26, 1996.													
50000000000000000000000000000000000000	ВІ	Abstract of HOSIE J. et al., "Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium," British Journal of Rheumatology, 35 Suppl. 1:39-43, April 1996.													
Recorders	ВЈ	Abstract of PAIRET M. et al., "Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications," Fundamental & Clinical Pharmacology 10(1):1-17, 1996.													
	ВК	Abstract of MASFERRER J.L. et al, "Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract," Gastroenterology Clinics of North America 25(2):363-72, June 1996.													
70000000000000000000000000000000000000	BL	Abstract of EMERY P., "Clinical implications of selective cycloxygenase-2 inhibiton," Scandinavian Journal of Rheumatology-Supplement 102:23-8, 1996.													
×0000000000000000000000000000000000000	ВМ	Van Hecken, Anne, et al., "Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers", J Clin Pharmacol (2000) 40: 1109-1120.													
999999	1 - 11	20%	<u> 701</u>			110			, o o						
	BN														
	во														
EXAMINER /Sue Liu/										DATE CONSIDERED 05/27/2008					
*EVANINED: tritial if reference considered whether or not citation is in conformance with MRER 600; Draw line through citation if not in															

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.